Countries China
RemeGen's RC88 Granted FDA IND Approval for Platinum-Resistant Ovarian Cancer
The open-label, randomized, dose optimization phase 2 study aims to enroll participants in multiple countries to further clarify the optimal dosage...
December 29, 2023 | News
Innovent and Xuanzhu Collaborate on Clinical Trial for Combined Therapy in Chinese Solid Tumor Treatment
Under the agreement, Innovent will supply sintilimab for the collaborated clinical trial. Xuanzhu Biopharma will conduct a Phase 1b clinical stud...
December 29, 2023 | News
PharmaBlock Sciences Unveils State-of-the-Art High Potency API Facility in Zhejiang Site.
The new HPAPI GMP facility enables PharmaBlock to offer process R&D and kilo-scale production of HPAPIs and ADC toxins. It spans an area of 1...
December 28, 2023 | News
FDA Grants Orphan Drug Designation to Boan Biotech's Two Novel Claudin 18.2 Drugs.
Orphan drugs, also known as drugs for rare diseases, are drugs for preventing, treating or diagnosing rare diseases. Being designated as orphan drugs will ...
December 28, 2023 | News
Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs
On December 20, NMPA has approved a clinical trial for JMKX003801 to treat serious infection caused by Gram-negative bacteria. Drug resistance of anti...
December 27, 2023 | News
GenSci Launches Global Innovation Hub in Shanghai
Changchun GeneScience Pharmaceutical ("GenSci"), a subsidiary of Changchun High-Tech Industries (Group), held a groundbreaking ceremony for its new global ...
December 26, 2023 | News
Oncoshot Collaborates with Zhejiang Ablaze for Data-Driven Drug Development in China
This collaboration brings together complementary strengths - Oncoshot's capabilities in data analysis and insights generation with Ablaze's recent expansio...
December 26, 2023 | News
TransThera Completes First Patient Dosing in US for Global Phase 3 Trial of Tinengotinib in FGFRi Relapsed/Refractory Cholangiocarcinoma
This study is a Phase 3, randomized, controlled, global multicenter study to evaluate the efficacy and safety of oral tinengotinib versus physician's choic...
December 22, 2023 | News
Everest Medicines' Partner Calliditas Announces Nefecon® as Sole FDA-Approved Treatment for Slowing IgA Nephropathy Kidney Decline
The FDA approval is for adults with primary IgAN who are at risk for disease progression, irrespective of proteinuria levels. Nefecon® is now a...
December 21, 2023 | News
BioCity Doses First Patient in Phase Ib/II Trial of BC3402 Anti-TIM-3 mAb with IMFINZI for Advanced Hepatocellular Carcinoma
The study is being conducted at Zhongshan Hospital with Prof. Jia Fan as the principal investigator. Dr. Fan is a world-renowned liver cancer sur...
December 21, 2023 | News
CellOrigin Treats First CAR-M Patient in China, Unveils Second-Gen CAR-M for Solid Tumors
"A single center, single-arm, dose-escalation, exploratory clinical trial to examine the safety, tolerability, pharmacokinetics and prelimina...
December 21, 2023 | News
InxMed Licenses Next-Gen ADCs with Escugen
The license agreement provides InxMed with right to use EZWi-Fit® platform on the several novel ADC candidate molecules. InxMed will hav...
December 20, 2023 | News
NMPA Accepts Mabwell's 8MW0511 Injection New Drug Application
8MW0511, a Class 1 therapeutic biological product, is a new generation of long-acting G-CSF (modified cytokine with high activity) with independent intelle...
December 20, 2023 | News
InnoCare's TYK2 Inhibitor ICP-332 Meets Phase II Endpoint in Atomic Dermatitis Study
ICP-332 in AD patients treated for 4 weeks demonstrated excellent efficacy and safety profile. ICP-332 achieved multiple efficacy endpoints including Eczem...
December 18, 2023 | News
Most Read
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2025
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
